For the year ending 2025-12-31, OKUR had -$51,711K decrease in cash & cash equivalents over the period. -$51,874K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Direct program expense | 28,373 |
| Indirect program expense | 1,923 |
| Workforce salaries and benefits | 16,301 |
| Share-based compensation expense | 11,633 |
| General corporate expenses | 4,720 |
| Interest and other expense | 8 |
| Interest income | 3,441 |
| Adjustments and reconciling items | 3,441 |
| Net loss | -59,517 |
| Share-based compensation expense | 11,633 |
| Depreciation and amortization | 447 |
| Amortization of right-of-use asset - operating | 383 |
| Loss on disposal of property and equipment | -6 |
| Prepaid and other assets | -289 |
| Accounts payable, accrued and other liabilities | -4,545 |
| Lease liabilities | -536 |
| Other long-term liabilities | 12 |
| Net cash used in operating activities | -51,828 |
| Purchases of property and equipment | 46 |
| Net cash (used in) provided by investing activities | -46 |
| Payment of issuance costs associated with the concurrent financing | 37 |
| Payment of reverse recapitalization transaction costs | 40 |
| Proceeds from sale of stock under the employee stock purchase plan | 240 |
| Net cash provided by financing activities | 163 |
| Net decrease in cash and cash equivalents | -51,711 |
| Cash and cash equivalents, beginning of period | 110,761 |
| Cash and cash equivalents, end of period | 59,050 |
OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (OKUR)